CERO

CERO

USD

CERo Therapeutics Holdings Inc. Common Stock

$0.095-0.240 (-71.620%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$0.335

最高价

$0.095

最低价

$0.095

成交量

8.44M

公司基本面

市值

177.4K

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

2.29M

交易所

NCM

货币

USD

52周价格范围

最低价 $0.062当前价 $0.095最高价 $896

相关新闻

Analyst Upgrades

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

Maxim Group analyst Jason McCarthy downgrades CERo Therapeutics Hldgs from Buy to Hold.

查看更多
Maxim Group Downgrades CERo Therapeutics Hldgs to Hold
Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

查看更多
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
GlobeNewswire

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

Trading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue

查看更多
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination
Analyst Upgrades

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target

D. Boral Capital analyst Jason Kolbert maintains CERo Therapeutics Hldgs with a Buy and maintains $30 price target.

查看更多
D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target
GlobeNewswire

CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML

Company completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.

查看更多
CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
GlobeNewswire

CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,